生物医药公司Intensity Therapeutics, Inc.近日宣布,将对其关键临床试验Invincible-4的研究方案进行修订,并计划在2026年第一季度重新启动患者招募工作。这一战略调整旨在优化试验设计,提升试验效率,为后续研发进程奠定更坚实的基础。
生物医药公司Intensity Therapeutics, Inc.近日宣布,将对其关键临床试验Invincible-4的研究方案进行修订,并计划在2026年第一季度重新启动患者招募工作。这一战略调整旨在优化试验设计,提升试验效率,为后续研发进程奠定更坚实的基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.